{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:20:44Z","timestamp":1793370044795,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"27","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Trastuzumab and anthracyclines, often used in the treatment of breast cancer, may impair myocardial function, and reduce left ventricular ejection fraction (LVEF), potentially causing heart failure. Randomized controlled trials (RCTs) have evaluated the effects of beta-blockers (BBs), angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme inhibitors (ACEI) on trastuzumab- and anthracycline-associated cardiotoxicity. We report a meta-analysis of these RCTs in patients with breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The primary analysis was on the effect of BBs and ACEI\/ARBs on LVEF in patients treated with either trastuzumab or anthracyclines. A secondary analysis was done investigating the effect of BBs or ACEI\/ARBs on LVEF in trastuzumab and anthracycline treatments. Only RCTs were included using the search term \u2018ARBs, ACEIs, BBs, anthracyclines, trastuzumab, and breast cancer\u2019 in PubMed, Embase, and CENTRAL up to 31 March 2021. A meta-analysis was conducted to estimate the mean difference (MD) in LVEF between intervention and placebo groups at follow-up. A total of nine RCTs (n\u2009=\u20091362) were included in the analysis. All patients were women. BBs and ACEI\/ARBs were shown to attenuate the decline in LVEF during trastuzumab and anthracycline treatments [MD: 2.4; 95% confidence interval (CI): 0.3\u20134.2 and MD: 1.5; 95% CI: \u20130.6 to 3.7]. Compared with placebo, LVEF was significantly higher in patients assigned to BB or ACEI\/ARB on trastuzumab (MD: 2.3; 95% CI: 0.0\u20134.6) but not on anthracyclines (MD: 1.9; 95% CI: \u20130.5 to 4.2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Both BB and ACEI\/ARB therapies were associated with the preservation of LVEF during trastuzumab and anthracycline-containing regimens as compared with placebo, suggesting both to be beneficial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab843","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T20:15:44Z","timestamp":1638994544000},"page":"2562-2569","source":"Crossref","is-referenced-by-count":91,"title":["A systematic review and meta-analysis of beta-blockers and renin\u2013angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-2178","authenticated-orcid":false,"given":"Christian","family":"Lewinter","sequence":"first","affiliation":[{"name":"Heart Centre, Karolinska University Hospital , Karolinska Universitetssjukhuset Solna, Solna, Stockholm 171 76 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten Holm","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet-Copenhagen University Hospital , Juliane Maries Vej 6, 2100 K\u00f8benhavn \u00d8 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Robert","family":"Edfors","sequence":"additional","affiliation":[{"name":"Heart Centre, Karolinska University Hospital , Karolinska Universitetssjukhuset Solna, Solna, Stockholm 171 76 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-6023","authenticated-orcid":false,"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[{"name":"Heart Centre, Karolinska University Hospital , Karolinska Universitetssjukhuset Solna, Solna, Stockholm 171 76 , Sweden"},{"name":"The Karolinska Institute , Nobels v\u00e4g 6, Solna, Stockholm 171 77 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-5334","authenticated-orcid":false,"given":"John Martin","family":"Bland","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Seebohm Rowntree Building University of York , Heslington, York YO10 5DD , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00a0M","family":"LeWinter","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, White River Junction Veterans Affairs Medical Center , 163 Veterans Dr, White River Junction, VT 05009 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John G F","family":"Cleland","sequence":"additional","affiliation":[{"name":"Institute of Health and Wellbeing, University of Glasgow , 1 Lilybank Gardens, Glasgow G12 8RZ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-1466","authenticated-orcid":false,"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Heart Centre, Rigshospitalet-Copenhagen University Hospital , Inge Lehmanns Vej 7, 2100 K\u00f8benhavn \u00d8 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4966-1315","authenticated-orcid":false,"given":"Frieder","family":"Braunschweig","sequence":"additional","affiliation":[{"name":"Heart Centre, Karolinska University Hospital , Karolinska Universitetssjukhuset Solna, Solna, Stockholm 171 76 , Sweden"},{"name":"The Karolinska Institute , Nobels v\u00e4g 6, Solna, Stockholm 171 77 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1478-0947","authenticated-orcid":false,"given":"Agneta","family":"Mansson-Broberg","sequence":"additional","affiliation":[{"name":"Heart Centre, Karolinska University Hospital , Karolinska Universitetssjukhuset Solna, Solna, Stockholm 171 76 , Sweden"},{"name":"The Karolinska Institute , Nobels v\u00e4g 6, Solna, Stockholm 171 77 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"2022102517025726800_ehab843-B1","author":"World Health Organisation (WHO)","year":"2019"},{"key":"2022102517025726800_ehab843-B2","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2022102517025726800_ehab843-B3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102517025726800_ehab843-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.015","article-title":"Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer","volume":"120","author":"Pivot","year":"2019","journal-title":"Eur J Cancer"},{"key":"2022102517025726800_ehab843-B5","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2022102517025726800_ehab843-B6","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0","author":"Higgins"},{"key":"2022102517025726800_ehab843-B7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: a time for change","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"key":"2022102517025726800_ehab843-B8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2022102517025726800_ehab843-B9","first-page":"40","volume-title":"Meta: An R Package for Meta-Analysis","author":"Schwarzer","year":"2007"},{"key":"2022102517025726800_ehab843-B10","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102517025726800_ehab843-B11","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022102517025726800_ehab843-B12","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"2022102517025726800_ehab843-B13","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102517025726800_ehab843-B14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity","volume":"69","author":"Nabati","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022102517025726800_ehab843-B15","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102517025726800_ehab843-B16","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022102517025726800_ehab843-B17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology"},{"key":"2022102517025726800_ehab843-B18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"key":"2022102517025726800_ehab843-B19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/COC.0000000000000389","article-title":"Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or \u03b2-blockers in older adults with breast cancer","volume":"41","author":"Wittayanukorn","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"2022102517025726800_ehab843-B20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-2999(01)00782-8","article-title":"Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat","volume":"414","author":"Sacco","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"2022102517025726800_ehab843-B21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2022102517025726800_ehab843-B22","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J"},{"key":"2022102517025726800_ehab843-B23","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies: trastuzumab cardiotoxicity","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2022102517025726800_ehab843-B24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00019501-199504000-00005","article-title":"Anti-remodeling effects of ACE inhibitors","volume":"6","author":"McDonald","year":"1995","journal-title":"Coron Artery Dis"},{"key":"2022102517025726800_ehab843-B25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/hrt.2007.136093","article-title":"Anthracycline associated cardiotoxicity in survivors of childhood cancer","volume":"94","author":"Lipshultz","year":"2008","journal-title":"Heart"},{"key":"2022102517025726800_ehab843-B26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","article-title":"CCS\/CHFS Heart Failure Guidelines Update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"2022102517025726800_ehab843-B27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","article-title":"Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients","volume":"28","author":"Stangier","year":"2000","journal-title":"J Int Med Res"},{"key":"2022102517025726800_ehab843-B28","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102517025726800_ehab843-B29","author":"Omland"},{"key":"2022102517025726800_ehab843-B30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1503\/cmaj.060410","article-title":"The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey","volume":"176","author":"Ioannidis","year":"2007","journal-title":"CMAJ"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/27\/2562\/46629530\/ehab843.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/27\/2562\/46629530\/ehab843.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T18:18:18Z","timestamp":1666721898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/27\/2562\/6482048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":30,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2021,12,24]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab843","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,14]]},"published":{"date-parts":[[2021,12,24]]}}}